These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 2057921

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro.
    Lijnen HR, Van Hoef B, De Cock F, Collen D.
    Blood; 1989 May 15; 73(7):1864-72. PubMed ID: 2713507
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M, Vandamme AM, Holvoet P, De Cock F, Lemmens G, Lijnen HR, Stassen JM, Collen D.
    Thromb Haemost; 1992 Aug 03; 68(2):170-9. PubMed ID: 1412163
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y, Scully MF, Ellis V, Kakkar VV.
    Thromb Haemost; 1989 Jun 30; 61(3):502-6. PubMed ID: 2508259
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O, Rijken DC, Collen D.
    Thromb Haemost; 1981 Jun 30; 45(3):225-9. PubMed ID: 7025339
    [Abstract] [Full Text] [Related]

  • 16. Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential.
    Lijnen HR, Wnendt S, Schneider J, Janocha E, Van Hoef B, Collen D, Steffens GJ.
    Eur J Biochem; 1995 Nov 15; 234(1):350-7. PubMed ID: 8529664
    [Abstract] [Full Text] [Related]

  • 17. Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line.
    Lijnen HR, Webb PD, Van Hoef B, De Cock F, Stassen JM, Prior SD, Collen D.
    Thromb Haemost; 1992 Feb 03; 67(2):239-47. PubMed ID: 1621244
    [Abstract] [Full Text] [Related]

  • 18. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M, Scopece S, Gelato AV, Dimonte D, Semeraro N.
    Thromb Haemost; 1997 Apr 03; 77(4):725-9. PubMed ID: 9134650
    [Abstract] [Full Text] [Related]

  • 19. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.
    Zamarron C, Lijnen HR, Van Hoef B, Collen D.
    Thromb Haemost; 1984 Aug 31; 52(1):19-23. PubMed ID: 6495259
    [Abstract] [Full Text] [Related]

  • 20. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
    Robbie LA, Booth NA, Croll AM, Bennett B.
    Thromb Haemost; 1993 Aug 02; 70(2):301-6. PubMed ID: 8236139
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.